Results 271 to 280 of about 1,151,684 (305)
Some of the next articles are maybe not open access.
Tumor-Targeting Theranostic Polymers
LangmuirTheranostic polymers have emerged as a versatile platform in cancer nanomedicine, integrating therapeutic and imaging functionalities to overcome challenges in oncology. Featuring diverse architectures such as linear polymers, dendrimers, star-like polymers, and bottle-brush polymers, these systems enable tumor-targeted drug delivery, real-time imaging,
Ying Wei, Mingfeng Wang
openaire +2 more sources
Drugs of the Future, 2006
Conventional tumor therapy typically suffers from a lack of specificity, leading to a poor therapeutic index and adverse events. The selective delivery of bioactive molecules to tumor sites represents an attractive therapeutic strategy, which promises to spare normal organs and yield medicinal agents with improved therapeutic ratios.
null Marlind, J. +2 more
openaire +1 more source
Conventional tumor therapy typically suffers from a lack of specificity, leading to a poor therapeutic index and adverse events. The selective delivery of bioactive molecules to tumor sites represents an attractive therapeutic strategy, which promises to spare normal organs and yield medicinal agents with improved therapeutic ratios.
null Marlind, J. +2 more
openaire +1 more source
2020
The rising prominence of cancer as a leading cause of death reflects therapeutic predicament over malignancy, leading to intensive efforts for tumor treatment. Anticancer precision medicine has shown great progress in recent years, holding promise to reduce side effects and improve treatment outcome.
Min Liu, Weiyue Lu
openaire +1 more source
The rising prominence of cancer as a leading cause of death reflects therapeutic predicament over malignancy, leading to intensive efforts for tumor treatment. Anticancer precision medicine has shown great progress in recent years, holding promise to reduce side effects and improve treatment outcome.
Min Liu, Weiyue Lu
openaire +1 more source
2020
Hypoxia (oxygen levels below 1–2%) is a common finding in solid tumors. The development of tumor hypoxia can be viewed as an imbalance between oxygen supply and demand. Tumor hypoxia significantly impacts tumor radiosensitivity and subsequently leads to poor clinical outcomes in patients treated with radiation therapy.
Michael Skwarski +4 more
openaire +1 more source
Hypoxia (oxygen levels below 1–2%) is a common finding in solid tumors. The development of tumor hypoxia can be viewed as an imbalance between oxygen supply and demand. Tumor hypoxia significantly impacts tumor radiosensitivity and subsequently leads to poor clinical outcomes in patients treated with radiation therapy.
Michael Skwarski +4 more
openaire +1 more source
Brain and other central nervous system tumor statistics, 2021
Ca-A Cancer Journal for Clinicians, 2021Kimberly D Miller +2 more
exaly
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
2017
At the end of the nineteenth century in 1894, Dr. Pierre-Paul Emile Roux from the Pasteur Institute in Paris demonstrated the clinical efficacy of serotherapy to treat diphtheria. A century later in 1994, Prof. Ronald Levy from Stanford University, CA, USA, demonstrated that antibodies could also be used to treat cancers. Since then, major improvements
openaire +1 more source
At the end of the nineteenth century in 1894, Dr. Pierre-Paul Emile Roux from the Pasteur Institute in Paris demonstrated the clinical efficacy of serotherapy to treat diphtheria. A century later in 1994, Prof. Ronald Levy from Stanford University, CA, USA, demonstrated that antibodies could also be used to treat cancers. Since then, major improvements
openaire +1 more source
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Ca-A Cancer Journal for Clinicians, 2021Michael L Cheng +2 more
exaly